14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CORT ranks #13960 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Corcept Therapeutics Incorporated Stock Forecast NASDAQ:CORT

$17.89 (1.59%)

Volume: 1M

Closed: Jan 19, 2022

Hollow Logo Score: -3.305

Corcept Therapeutics Incorporated Stock Forecast

$17.89 (1.59%)

Volume: 1M

Closed: Jan 19, 2022

Score Hollow Logo -3.305

Corcept Therapeutics Incorporated Company Profile

149 Commonwealth Drive

Menlo Park CA 94025



Industry: Biotechnology

Sector: Healthcare

Corcept Therapeutics Incorporated


Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. Its products include Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, Korlym’s active ingredient, which is in Phase I/II clinical trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with metastatic, triple-negative breast cancer, a form of solid-tumor cancer with a particularly poor prognosis; and CORT125134 that is in Phase I clinical trials for the treatment of patients with Cushing’s syndrome and solid-tumor cancers. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE